VeriSIM Life (VeriSIM), a San Francisco-based the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, announced it closed its oversubscribed $15 million Series A round.
The financing was led by Morpheus Ventures. Additional new investors include Debiopharm Innovation Fund and Colorcon Ventures, with continued support from existing investors OCA Ventures, Intel Capital, Serra Ventures, and Susa Ventures.
This new funding will allow VeriSIM to accelerate its growth and bring the future of more efficient, cost-effective clinical trials to life.
Company: VeriSIM Life, Inc.
Round: Series A
Funding Month: January 2022
Lead Investors: Morpheus Ventures
Additional Investors: Debiopharm Innovation Fund, Colorcon Ventures, OCA Ventures, Intel Capital, Serra Ventures, and Susa Ventures
Company Website: https://www.verisimlife.com/
Software Category: AI-driven drug development engine
About the Company: Founded in 2017 by Dr. Jo Varshney, DVM, and Ph.D., alongside a truly cross-functional team of pharmaceutical scientists, software engineers, and AI/ML and simulation experts. VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to significantly improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases.